0001209191-15-044673.txt : 20150519 0001209191-15-044673.hdr.sgml : 20150519 20150519192559 ACCESSION NUMBER: 0001209191-15-044673 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150515 FILED AS OF DATE: 20150519 DATE AS OF CHANGE: 20150519 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ruegg Curtis CENTRAL INDEX KEY: 0001597578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 15877915 MAIL ADDRESS: STREET 1: 7555 GATEWAY BOULEVARD CITY: NEWARK STATE: CA ZIP: 94560 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-05-15 0 0001479290 Revance Therapeutics, Inc. RVNC 0001597578 Ruegg Curtis C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK CA 94560 0 1 0 0 EVP, Technical Operations Common Stock 2015-05-15 4 M 0 500 6.60 A 19837 D Common Stock 2015-05-15 4 S 0 500 25.00 D 19337 D Common Stock 2015-05-18 4 M 0 2500 6.60 A 21837 D Common Stock 2015-05-18 4 S 0 500 26.695 D 21337 D Common Stock 2015-05-18 4 S 0 500 26.679 D 20837 D Common Stock 2015-05-18 4 S 0 500 26.684 D 20337 D Common Stock 2015-05-18 4 S 0 1000 26.718 D 19337 D Stock Option (Right to Buy) 6.60 2015-05-15 4 M 0 500 0.00 D 2016-12-11 Common Stock 500 7836 D Stock Option (Right to Buy) 6.60 2015-05-18 4 M 0 2500 0.00 D 2016-12-11 Common Stock 2500 5336 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.875, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.02 to $26.885, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The Option is fully vested as of September 29, 2010. /s/ Gordon Ho, Attorney-in-fact 2015-05-19